Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Astellas Pharma : ITI Announces Promotion of Dr. Tim Coleman to SVP, Operations and GM

10/23/2020 | 10:25am EST

ROCKVILLE - Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the promotion of Dr. Tim Coleman to the newly created role of Senior Vice President, Operations and General Manager.

Dr. Coleman joined ITI in 2015, and during his tenure with the company, has played a key role in managing several functional areas including operations, process development, facilities and IT. In particular, Dr. Coleman has successfully managed the manufacturing activities of ITI's lead candidates with strategic partners like Astellas Pharma ('Astellas') and CMOs like VGXI, Aldevron and Hitachi Chemical Advanced Therapeutic Solutions ('HCATS'). In his new role, Dr. Coleman will broaden his scope of responsibilities in these areas and will continue to be a contributing member of the executive leadership team.

'Tim has dedicated the last five plus years to building and growing ITI and we are thrilled to have him step into an expanded role as Senior Vice President and General Manager. His proven ability to deliver results, combined with his in-depth knowledge of our science, partnerships and company culture, will be invaluable to us as we transition into the next phase of our growth,' said William G. Hearl, CEO of Immunomic Therapeutics. 'ITI is on a very positive trajectory and we look forward to building upon this momentum with Tim taking a larger role.'

Prior to joining ITI, Dr. Coleman served as Senior Director of New Product Development at SeraCare Life Sciences in Gaithersburg, MD. Dr. Coleman also held leadership roles at Lonza Bioscience, Inc. where he oversaw product development and quality control departments as well as Human Genome Sciences where he helped establish the Protein Development department. Dr. Coleman has authored more than 40 publications and 26 issued patents. He obtained his B.A. degree from Rutgers University in Newark, New Jersey and a Ph.D. in Molecular and Cellular Biology from Ohio University.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses. ITI's UNITE platform could potentially have broad therapeutic applications in oncology, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics and ITI has built a large pipeline from UNITE with six oncology programs and two allergy programs. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. ITI maintains its headquarters in Rockville, Maryland.

Contact:

Tel: +1.301.968.3501

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ASTELLAS PHARMA INC.
11/30Astellas Receives Approval of EVRENZO in Japan for the Treatment of Anemia of..
AQ
11/26ASTELLAS PHARMA : Launches a 'Contact for Potential Acquisition of ' R&D Program..
AQ
11/18Japan shares fall as virus surge, firmer yen weigh
RE
11/17ASTELLAS PHARMA : to Present New Data on Gilteritinib in FLT3 Mutation-Positive ..
AQ
11/09ASTELLAS PHARMA INC. : - XTANDI Approved by China NMPA for the Treatment of Non-..
AQ
11/02ASTELLAS PHARMA : Completes Acquisition of iota Biosciences
AQ
10/30Japan stocks fall, post biggest weekly loss in 3 months on virus worries
RE
10/29Japanese shares slump on virus worries, mixed earnings
RE
10/28ASTELLAS PHARMA : Receives U.S. FDA Fast Track Designation for ASP5354, an Inves..
AQ
10/27ASTELLAS PHARMA INC. : half-yearly earnings release
More news
Financials
Sales 2021 1 273 B 12 179 M 12 179 M
Net income 2021 194 B 1 853 M 1 853 M
Net cash 2021 444 B 4 247 M 4 247 M
P/E ratio 2021 14,3x
Yield 2021 2,80%
Capitalization 2 789 B 26 727 M 26 680 M
EV / Sales 2021 1,84x
EV / Sales 2022 1,66x
Nbr of Employees 15 883
Free-Float 99,2%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 2 287,50 JPY
Last Close Price 1 501,50 JPY
Spread / Highest target 113%
Spread / Average Target 52,3%
Spread / Lowest Target 13,2%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.-20.67%26 407
JOHNSON & JOHNSON-0.82%380 876
ROCHE HOLDING AG-4.76%282 467
PFIZER, INC.3.21%212 942
NOVARTIS AG-10.48%206 479
MERCK & CO., INC.-11.61%203 389